Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): Res…
R Porschen, HT Arkenau, S Kubicka, T Seufferlein, U Graeven, P Freier, A Grothey, A Hinke, HJ Schmoll, C Englisch-Fritz · Zeitschrift für Gastroenterologie · 2006 · Heft 04
Bibliografische Angaben
Zusammenfassung
Aims: In a previous phase III study the FUFOX regimen has shown superior response rates to bolus 5-FU/FA (Mayo Clinic protocol) in patients with MCRC (Grothey, ASCO 2002). The combination of capecitabine (CAP) and oxaliplatin (OX) has demonstrated good efficacy and safety results in recent phase II studies. In August 2002 we initiated a phase III trial to compare FUFOX and CAPOX as first line therapy in patients with MCRC. Here, we present the results of the planned interim safety and efficacy analysis. Patients and methods: From August 2002 to August 2004 476 patients (m: f=299: 177; median age 65 (range 32–86)…
